Vijaya Diagnostic Centre Limited has informed the Exchange regarding Grant of 191150 Options.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts less than Nifty Smallcap 250 and 3.5 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vijaya Diagnostic Centre's Board of Directors met on May 12, 2025, and approved the audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with the statutory auditors issuing an unmodified (clean) opinion. The Board recommended a final dividend of ₹2 per equity share (200% on face value of ₹1), subject to shareholder approval at the upcoming AGM. Mr. S. Ramachandra Reddy was appointed as Interim Chief Financial Officer, and Mr. Lanka Sai Srinivas was appointed as Chief Technology Officer, both effective May 12, 2025. M/s. Santhosh & Associates were re-appointed as Cost Auditors for FY 2025-26. Additionally, the Nomination and Remuneration Committee granted 1,91,150 Employee Stock Options (ESOPs) under the VDCL ESOP Plan 2018 at an exercise price of ₹815 per option, with vesting starting after one year and a 10-year exercise period.
The clean audit opinion and ₹2 dividend signal financial stability and shareholder returns, while the new CFO and CTO appointments suggest leadership transitions that investors should monitor. The ESOP grant at ₹815 will create potential future dilution of up to 1.91 lakh shares once vested and exercised.